Background: Moderate and high efficacy disease modifying therapies (DMTs) have a
profound effect on disease activity. The current treatment guidelines only recommend high …

Dimethyl fumarate (DMF) is a widely used oral disease-modifying therapy for multiple
sclerosis (MS). Its efficacy and safety profiles are supported by over a decade of experience …

Abstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod,
ponesimod, and siponimod) are approved by the US Food and Drug Administration for the …

Humans have extensive adverse exposure to alpha, beta-unsaturated carbonyl compounds
(ABuCs) as these are major toxins in smoke and exhaust fumes, as well as products of lipid …

Background: With many disease-modifying therapies currently approved for the
management of multiple sclerosis, there is a growing need to evaluate the comparative …

Background Treatment switching is a common challenge and opportunity in real-world
clinical practice. Increasing diversity in disease-modifying treatments (DMTs) has generated …

Background To compare the effectiveness of dimethyl fumarate (DMF) with subcutaneous
interferon beta-1a (IFNβ-1a) in controlling disease activity in patients with relapsing …

Background: Although the aggregate of data among patients with multiple sclerosis (MS)
have shown similar efficacy between dimethyl fumarate (DMF) and fingolimod (FTY), most …

Multiple sclerosis (MS) is a chronic autoimmune neurological disorder that significantly
impacts the central nervous system (CNS), which includes the brain and spinal cord …

Aim To evaluate the real-world comparative effectiveness and the cost-effectiveness, from a
UK National Health Service perspective, of natalizumab versus fingolimod in patients with …